Clovis trades up on Leerink chatter but AstraZeneca drug may be threat

Clovis Oncology (CLVS +1.9%) reverses opening losses to trade higher.

There's chatter that a late breaker European Cancer Congress abstract for AstraZeneca's (AZN -0.6%) EGFR inhibitor AZD9291 is bad news for CLVS' CO-1686 (see also ARIA's AP26113).

However, an upbeat note out of Leerink seems to be driving bullish sentiment. The firm apparently thinks CLVS is worth between $96-140/share (so a really narrow range there) even without a takeout premium.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs